WATERTOWN, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a…
NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline…
BOSTON, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that…
SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development…
GAITHERSBURG, Md., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr.…
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a global company dedicated to unraveling the mysteries…
IRVINE, Calif., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Clinical Laserthermia Systems AB (publ) (CLS AB) (Stockholm: CLS B), developer of high…
GENEVA, Switzerland January 3, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies…
CAMBRIDGE, Mass., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of…
Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid’s franchise of potential first-in-class…